News zum Sektor Gesundheit aus Indien

 

India's top bourse will add the country's number one airline company and the most valuable hospital chain by market capitalization to its benchmark index at the end of September....

Fitch Ratings cautions that while Indian corporates have limited direct exposure to current US tariffs, sectors like pharmaceuticals could face risks if further measures are imposed. The US has levied a 25% tariff on Indian goods since August 7, 2025, with another 25% due on August 27, due to India's Russian oil imports....

India and China are set to discuss a trade package focusing on essential commodities like rare earth magnets, fertilizers, and pharmaceuticals, coinciding with PM Modi's SCO summit attendance. This move signals improving relations amid US trade tensions and India's need for Chinese imports....

Despite increased tariffs on Indian imports, the US has temporarily exempted the pharmaceutical sector, recognizing India's critical role in supplying affordable medicines. Pharmexcil emphasizes that tariffs on Indian pharma would harm American consumers, as Indian companies produce low-cost generics. India supplies over 40% of US generic medicines, maintaining high quality standards with numerous FDA-approved facilities....

Coming just days after Trump re-set his tariff plan with rates on imports from trade partners ranging from 10% to 41%, his latest blast of trade threats and deadlines shows his quest to remake global trade in America's favor is far from done. That's even as the latest economic data suggests the US economy is grappling with the fallout.  “We'll be putting a initially small tariff on pharmaceuticals, but in one year — one and a half years, maximum — it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country,” Trump said Tuesday in the interview on CNBC.  The Opening Trade has everything you need to know as markets open across Europe. With analysis you won't find anywhere else, we break down the biggest stories of the day and speak to top guests who have skin in the game. Hosted by Kriti Gupta, Valerie Tytel and Oliver Crook. (Source: Bloomberg)...

Um den gesamten Artikel unter timesofindia.indiatimes.com zu lesen, klicken Sie bitte auf die Überschrift...

India's pharma sector has downplayed the impact of US President Trump's 25% tariff, warning instead of severe consequences for American healthcare. Industry leaders stressed India's key role in supplying affordable medicines to the US and predicted shortages, higher costs, and a 3–5 year struggle for the US to find alternatives....

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

Glenmark Pharmaceuticals Ltd.'s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian biotechnology stocks, with some brokerages calling it the largest such deal in the country....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Before the trading day starts we bring you a digest of the key news and events that are likely to move markets. Today we look at:...

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S's Ozempic and Wegovy in key markets as it races to be among the first few to reap a windfall after patents on the blockbuster weight-loss drugs expire next year....

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug targets India's large obese population. The company aims to create awareness and collaborate with stakeholders to combat obesity, citing its significant impact on India's GDP....

Um den gesamten Artikel unter onvista.de zu lesen, klicken Sie bitte auf die Überschrift...

Novo Nordisk A/S will tailor the pricing of its blockbuster weight-loss treatment Wegovy in India to align with local demand, as it looks to fend competition from Eli Lilly & Co. in a nation with the world's third-largest obese population....

Amazon India has introduced at-home diagnostics services in six major cities, expanding its healthcare offerings under Amazon Medical. In collaboration with Orange Health Labs, Amazon Diagnostics enables users to book lab tests, schedule appointments, and access digital reports via the Amazon app. This integration of pharmacy, clinic, and diagnostics aims to provide a comprehensive digital healthcare experience....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

India's trade with the G7 nations has experienced substantial growth, reaching $248 billion in FY25 with a 13% CAGR since FY21. Exports to the G7 hit $138 billion, while imports totaled $110 billion. India maintains a $28 billion trade surplus, driven by key sectors like telecom equipment and pharmaceuticals, with mobile phone exports surging by 55%....

Bupa, a British health insurance giant, is planning to expand into India's rapidly growing private healthcare market, aiming to establish hospitals and clinics. Recognizing India's under-penetrated insurance market and significant growth potential, Bupa intends to replicate its 'Payvider' model, integrating insurance with healthcare provision....